article
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
List view / Grid view
Hit-to-Lead
news
Novel PF74-like small molecules developed to target HIV capsid protein
Scientists have developed PF74-like small molecules able to target the HIV-1 capsid protein, identifying four potent compounds.
webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
news
X-ray screening reveals two promising SARS-CoV-2 drug candidates
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
article
Expanding accessible chemical space through automated high-throughput experimentation
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
article
How RNA therapeutics can be used to treat retinitis pigmentosa
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
news
Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
news
Inexpensive drug protects against COVID-19 inflammation in pre-clinical trials
A drug called topotecan (TPT) was administered to mice up to four days after COVID-19 infection, reducing inflammation and morbidity.
article
COVID-19 drug targets and cell-based assays
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified…
news
Aptamer inhibits SARS-CoV-2 with novel mechanism of action, study shows
An aptamer that can bind a different part of SARS-CoV-2 than known inhibitors could enhance treatments against coronavirus mutations.
whitepaper
Whitepaper: Simple Western™ produces publication-ready results
Simple Western™ is an automated capillary immunoassay that produces publication-ready data to meet the highest standards of data integrity and rigor.
whitepaper
Catalogue: Nuclease-Free tubes, tips & buffers
Working with RNA requires rigorous nuclease contamination controls in place. Stock up on Nuclease-Free tubes tips and buffers #Back2Lab
news
Antisense oligonucleotide with potential to combat COVID-19 developed
Scientists have designed a compound named ASO-1 that could help to reduce immune response overactivation in patients with COVID-19.
whitepaper
Catalogue: Ribosomal RNA from bacteria with RiboMinus
RiboMinus Bacteria 2.0 Transcriptome Isolation Kits perform efficient transcriptome enrichment from total bacterial RNA. Improve your RNA extraction from bacteria today.